

Olga Reshetko

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8668791/publications.pdf>

Version: 2024-02-01

18
papers

5,942
citations

932766

10
h-index

1058022

14
g-index

19
all docs

19
docs citations

19
times ranked

7707
citing authors

#	ARTICLE	IF	CITATIONS
1	Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2013, 369, 1327-1335.	13.9	2,261
2	Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2018, 379, 2097-2107.	13.9	2,211
3	Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. <i>New England Journal of Medicine</i> , 2017, 376, 1527-1539.	13.9	510
4	Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. <i>New England Journal of Medicine</i> , 2016, 375, 534-544.	13.9	379
5	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 618-628.	5.5	207
6	Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1009-1019.	0.5	180
7	FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, iii19-iii32.	1.3	112
8	Comparison of Fatal or Irreversible Events With Extendedâ€Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	40
9	One or two doses of live varicella virus-containing vaccines: Efficacy, persistence of immune responses, and safety six years after administration in healthy children during their second year of life. <i>Vaccine</i> , 2018, 36, 381-387.	1.7	21
10	Primary efficacy of netakimab, a novel interleukin-17 inhibitor, in the treatment of active ankylosing spondylitis in adults. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 27-34.	0.4	15
11	Pharmacological Safety in Pregnancy: A Systematic Review On the Use of Potentially Teratogenic Drugs. <i>PediatricĀeskaĀ FarmakologiĀ</i> , 2017, 14, 127-141.	0.1	3
12	A randomized trial assessing the efficacy, immunogenicity, and safety of vaccination with live attenuated varicella zoster virus-containing vaccines: ten-year follow-up in Russian children. <i>Human Vaccines and Immunotherapeutics</i> , 2021, , 1-12.	1.4	1
13	The rationality of recommendations of drugs for patients with cephalgia in simulated situations in the pharmacy. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2022, , 27-43.	0.2	1
14	Evaluation of adherence of patients with atrial fibrillation to anticoagulant therapy at the outpatient stage of treatment. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2021, , 50-56.	0.2	1
15	PHARMACOTHERAPY AND OUTCOMES OF ACUTE ST-ELEVATION MYOCARDIAL INFARCTION â€“ GENDER DIFFERENCES IN REAL CLINICAL PRACTICE. <i>Rational Pharmacotherapy in Cardiology</i> , 2013, 9, 650-654.	0.3	0
16	COMPARATIVE ANALYSIS OF HOSPITAL PHARMACOTHERAPY OF CHRONIC HEART FAILURE WITH REDUCED LEFT VENTRICULAR EJECTION FRACTIONS IN 2009-2010 AND 2014-2015. <i>Rational Pharmacotherapy in Cardiology</i> , 2018, 14, 21-26.	0.3	0
17	Federation Pharmacological Safety in Pregnancy: Modern Knowledge, Practice and Pharmacoepidemiological Approaches to the Studying and Recognizing of Drugs with Teratogenic Risk. <i>PediatricĀeskaĀ FarmakologiĀ</i> , 2019, 16, 19-29.	0.1	0
18	Analysis of the consumption volumes of antithrombotic drugs used for pharmacotherapy of atrial fibrillation in Saratov Region. <i>Farmakoekonomika</i> , 2022, 14, 462-467.	0.4	0